Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00641_DB00661_nanopub.RAJcj6iPxYduwpvf_DAgbUMiUvErvW9fXQrFVu56BG7Lg#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00641_DB00661 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00641_DB00661 label "DDI between Simvastatin and Verapamil - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed. [drugbank_resource:DB00641_DB00661]" assertion.
- drugbank_resource:DB00641_DB00661 identifier "drugbank_resource:DB00641_DB00661" assertion.
- drugbank_resource:DB00641_DB00661 title "DDI between Simvastatin and Verapamil - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed." assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00641_DB00661 assertion.
- drugbank:DB00641 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00641_DB00661 assertion.